Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
A phase 2 trial of adebrelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Air Force Military Medical University, China, now recruiting.
Overview
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer is a phase 2 interventional study registered as NCT07569679 by Air Force Military Medical University, China, with a registry enrolment figure of 124 participants, started 2025-12-10 and due to reach its primary completion in 2028-12-30. Interventions recorded: HAIC, Gemcitabine plus Cisplatin, Adebrelimab, Apatinib. Conditions listed: Biliary Tract Cancer. Gallbladder cancer is named in the registry entry: "2. Histologically or cytologically confirmed diagnosis unresectable, locally advanced, or metastatic BTC, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer.". Sites: China. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAdebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Shares Adebrelimab, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialChemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
Shares Adebrelimab, Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialPerioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialQL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialEnvafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialStudy of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialThe Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialChidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.